Sobhan Faezi - Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran
Ahmad Reza Bahrmand - Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran
Seyed Davar Siadat - Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran
Iraj Nikokar - Department of Biotechnology, Laboratory of Microbiology and Immunology of Infectious Diseases, Para Medicine Faculty, Guilan University of Medical Sciences, Rasht, Iran
Soroush Sardari - Biotechnology Research Center, Drug Design and Bioinformatics Group, Pasteur Institute of Iran, Tehran, Iran
Mehdi Mahdavi - Departments of Immunology, Pasteur Institute of Iran, Tehran, Iran

Objective(s): Infection with Pseudomonas aeruginosa has been a long-standing obstacle for clinical therapy due to the complexity of the genetics and pathogenesis, as well for widespread resistance to antibiotics, thus attaching great importance to explore effective vaccines for prevention and treatment. This paper focuses on the introduction of novel Pseudomonas aeruginosa type IV pili (T۴P)-based fusion protein containing the secretin domain of PilQ and tandem PilA-related peptides. Materials and Methods: We surveyed the expression of the PilQ۳۸۰-۷۰۵-PilA fusion protein in-frame with pET۲۶b vector in which a rigid linker was used between two polypeptides and flexible linkers were inserted between the three tandem repeats and each pilA domains. The  transformants were  expressed in Escherichia coli BL۲۱. The reactivity of specific antisera to the fusion protein was assessed by ELISA. The biological activities of this candidate vaccine were evaluated by western blotting, opsonophagocytosis, and twitching inhibition assays. Results: The fusion protein was purified in high yield by osmotic shock method using HisTrap affinity column. The protein was confirmed by immunoblot analysis. The checkerboard titration showed that the optimal dilution of the antibody to react with antigen is ۱:۱۲۸. Results of opsonophagocytosis assay revealed that the antibodies elevated to the fusion protein promoted phagocytosis of the PAO۱ and ۶۲۶۶E strains, so that the twitching immobilization test confirmed these results. Conclusion: Due to excellent killing activity mediated by opsonic antibodies and efficient immobilization of the strains, it seems that PilQ۳۸۰-۷۰۵-PilA fusion protein could be a reliable candidate vaccine against P. aeruginosa infection.

Fusion protein, pET۲۶b, PilA, PilQ, Pseudomonas aeruginosa, Type IV pili